Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | MMP3 | P08254 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395877 | 0.89 | FPR2 (0.67) | FPR2KMT2ALDHAMMP3PPARG | |
| SCHEMBL3156701 | 0.87 | ALDH1A1 (0.54) | FPR2KMT2APPARGPPARAMMP2 | |
| SCHEMBL428265 | 0.87 | ALDH1A1 (0.54) | FPR2KMT2APPARGPPARAMMP2 | |
| SCHEMBL7390734 | 0.80 | ALDH1A1 (0.67) | FPR2KMT2AALDH1A1ALOX15 | |
| SCHEMBL5215651 | 0.80 | ALDH1A1 (0.67) | FPR2KMT2AALDH1A1ALOX15 | |
| SCHEMBL1702272 | 0.79 | PPARG (0.47) | MMP3PPARGPPARAMMP1ALDH1A1 | |
| SCHEMBL12157350 | 0.78 | FPR2 (0.64) | FPR2KMT2ALDHAPPARGPPARA | |
| SCHEMBL16116802 | 0.77 | LDHA (0.63) | FPR2KMT2ALDHAPPARGPPARA | |
| SCHEMBL839542 | 0.77 | LDHA (0.63) | FPR2KMT2ALDHAPPARGPPARA | |
| SCHEMBL5505712 | 0.77 | KMT2A (0.41) | FPR2KMT2ALDHAMMP3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324870-A | Improved peptide drugs for insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4397374-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mederis Diabetes, LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-117903257-A | Improved peptide drugs for insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11911447-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES LLC (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117582516-A | Improved peptide drugs against insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-3155017-B1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117180445-A | Improved peptide drugs against insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-110536696-B | PCSK9 vaccine based on novel peptides | 载度思生命科学有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-113264994-A | Improved peptide drugs against insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2021-08-17 | — | — | CN | disclosed |
| US-11065304-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2021-07-20 | — | — | US | disclosed |
| EP-2922876-B1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180194826-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | HERCULES CAPITAL, INC., AS AGENT | 2018-07-12 | — | — | US | disclosed |
| US-9856306-B2 | Peptide pharmaceuticals for insulin resistance | SPITFIRE PHARMA, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3155017-A1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mederis Diabetes, LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20170096468-A1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | HERCULES CAPITAL, INC., AS AGENT | 2017-04-06 | — | — | US | disclosed |
| WO-2015184177-A1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES, LLC (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20150290334-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | HERCULES CAPITAL, INC., AS AGENT | 2015-10-15 | — | — | US | disclosed |
| EP-2922876-A1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mederis Diabetes, LLC (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014081872-A1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES, LLC (US) | 2014-05-30 | — | — | WO | disclosed |
| EP-2231701-B1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP-1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LTD (IN) | 2012-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065304-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, PTMS | FPR2 1050/4885KMT2A 4134/4885LDHA 2286/4885 |
| US-20150290334-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | FPR2 1050/4885KMT2A 4134/4885LDHA 2286/4885 |
| US-11911447-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, PTMS | FPR2 1050/4885KMT2A 4134/4885LDHA 2286/4885 |
| US-20170096468-A1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, PTMS, GLP1R | FPR2 1220/4885KMT2A 3980/4885LDHA 2845/4885 |
| US-20180194826-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | FPR2 1050/4885KMT2A 4134/4885LDHA 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.